

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9350457/publications.pdf Version: 2024-02-01



DENCL

#	Article	IF	CITATIONS
1	Reprogramming of T Cells to Natural Killer–Like Cells upon <i>Bcl11b</i> Deletion. Science, 2010, 329, 85-89.	6.0	294
2	Establishment of porcine and human expanded potential stem cells. Nature Cell Biology, 2019, 21, 687-699.	4.6	261
3	Current status and perspectives of patient-derived xenograft models in cancer research. Journal of Hematology and Oncology, 2017, 10, 106.	6.9	214
4	IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. Journal of Hematology and Oncology, 2021, 14, 118.	6.9	106
5	A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2018, 11, 25.	6.9	80
6	Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. Journal of Hematology and Oncology, 2019, 12, 18.	6.9	79
7	Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells. Leukemia, 2018, 32, 801-808.	3.3	77
8	Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. Journal of Hematology and Oncology, 2017, 10, 68.	6.9	70
9	Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments. Journal of Hematology and Oncology, 2015, 8, 59.	6.9	43
10	DEPTOR is a direct NOTCH1 target that promotes cell proliferation and survival in T-cell leukemia. Oncogene, 2017, 36, 1038-1047.	2.6	39
11	Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells. Oncogene, 2021, 40, 1476-1489.	2.6	39
12	ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells. Haematologica, 2015, 100, 585-594.	1.7	38
13	Genome-wide analyses identify KLF4 as an important negative regulator in T-cell acute lymphoblastic leukemia through directly inhibiting T-cell associated genes. Molecular Cancer, 2015, 14, 26.	7.9	27
14	IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia, 2021, 35, 1380-1391.	3.3	26
15	SHQ1 regulation of RNA splicing is required for T-lymphoblastic leukemia cell survival. Nature Communications, 2018, 9, 4281.	5.8	24
16	Loss of Angiopoietin-like 7 diminishes the regeneration capacity of hematopoietic stem and progenitor cells. Journal of Hematology and Oncology, 2015, 8, 7.	6.9	21
17	Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized. Journal of Hematology and Oncology, 2016, 9, 94.	6.9	15
18	High level expression and purification of active recombinant human interleukin-15 in Pichia pastoris. Journal of Immunological Methods, 2016, 428, 50-57.	0.6	14

Peng Li

#	Article	IF	CITATIONS
19	The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells. Targeted Oncology, 2017, 12, 677-687.	1.7	13
20	CRISPR/Cas9-Mediated Deletion of Foxn1 in NOD/SCID/IL2rgâ^'/â^' Mice Results in Severe Immunodeficiency. Scientific Reports, 2017, 7, 7720.	1.6	12
21	The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection. Leukemia, 2020, 34, 2790-2793.	3.3	8
22	Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors. EMBO Reports, 2022, , e54275.	2.0	5
23	Low-Dose Triptolide Enhanced Activity of Idarubicin Against Acute Myeloid Leukemia Stem-like Cells Via Inhibiting DNA Damage Repair Response. Stem Cell Reviews and Reports, 2021, 17, 616-627.	1.7	4
24	Human induced-T-to-natural killer cells have potent anti-tumour activities. Biomarker Research, 2022, 10, 13.	2.8	4
25	Reprogramming mature terminally differentiated adipocytes to induced pluripotent stem cells. Science Bulletin, 2015, 60, 1752-1758.	4.3	3
26	DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D. Molecular Therapy - Oncolytics, 2022, 26, 15-26.	2.0	3
27	Expression and efficient purification of tag-cleaved active recombinant human insulin-like growth factor-II from Escherichia coli. Biotechnology and Bioprocess Engineering, 2015, 20, 234-241.	1.4	1